Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 5911.084 | 0.1287 | -0.7287 | 1.0262 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 5912.084 | 0.9345 | 0.8802 | 1.0966 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 5912.084 | 0.9742 | 0.9528 | 1.0966 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 5912.084 | 0.9651 | 0.9363 | 1.0966 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 5912.084 | 0.9623 | 0.9312 | 1.0966 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 5912.084 | 0.9798 | 0.9631 | 1.0966 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 5912.084 | 0.9230 | 0.8591 | 1.0966 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 5912.084 | 0.9836 | 0.9700 | 1.0966 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 5912.084 | 0.8005 | 0.6327 | 1.0966 | |
| CAMA-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 5912.084 | 0.7118 | 0.4668 | 1.0966 | |
| HBL-100 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7429.084 | 1.0010 | 1.0009 | 2.2510 | |
| HBL-100 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7429.084 | 1.0438 | 1.0384 | 2.2510 | |
| HBL-100 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7429.084 | 1.0005 | 1.0004 | 2.2510 | |
| HBL-100 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7429.084 | 1.0014 | 1.0012 | 2.2510 | |
| HBL-100 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7429.084 | 0.9614 | 0.9653 | 2.2510 | |
| HBL-100 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7429.084 | 0.9524 | 0.9571 | 2.2510 | |
| HBL-100 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7429.084 | 0.6695 | 0.6735 | 2.2510 | |
| HBL-100 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7429.084 | 0.0124 | -0.7151 | 2.2510 | |
| HBL-100 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7429.084 | 0.0071 | -0.7786 | 2.2510 | |
| HCC1143 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 7430.085 | 0.9836 | 0.9832 | 1.9592 | |
| HCC1143 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 7430.085 | 1.0441 | 1.0445 | 1.9592 | |
| HCC1143 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 7430.085 | 0.9964 | 0.9964 | 1.9592 | |
| HCC1143 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 7430.085 | 1.0778 | 1.0780 | 1.9592 | |
| HCC1143 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 7430.085 | 1.0215 | 1.0219 | 1.9592 | |
| HCC1143 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 7430.085 | 1.0632 | 1.0636 | 1.9592 |